

Human CD30, His Tag, HEK293

Catalog Number LDG041PHM

Package 5 µg / 20 µg / 100 µg / Customized package

For full product information, images and publications, please visit [our website](#).



Specifications

Species of Origin

Human

Affinity Tag

His Tag (C-term)

Purity

>95% as determined by SDS-PAGE analysis.

Endotoxin Level

<0.1 EU per 1 µg of the protein by the LAL method.

Expression System

HEK293

Storage Buffer

Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.

Molecular weight

The protein has a calculated MW of 39.25 kDa. The protein migrates as 55-75 kDa under reducing condition (SDS-PAGE analysis).

Form

Lyophilized

Background

Tainan Headquarter

+886-6-2536677

bd@leadgene.com.tw

Innovation & Research Center

+886-2-27065528

CLD Center

+886-6-2536677

Background

Human CD30, also known as TNFRSF8 (Tumor Necrosis Factor Receptor Superfamily Member 8), is a cell surface glycoprotein belonging to the tumor necrosis factor receptor (TNFR) superfamily. It is primarily expressed on activated T and B lymphocytes and plays a crucial role in immune regulation and inflammation. CD30 activation triggers signaling pathways involved in cell proliferation, survival, and cytokine production, contributing to the modulation of immune responses. Aberrant CD30 expression is associated with various lymphoproliferative disorders, including Hodgkin's lymphoma, anaplastic large cell lymphoma, and other malignancies. Therapeutically, CD30 has emerged as a promising target for antibody-based immunotherapy, such as antibody-drug conjugates, which selectively deliver cytotoxic agents to CD30-expressing tumor cells, demonstrating efficacy in the treatment of CD30-positive malignancies. Understanding the multifaceted roles of CD30 in immune regulation and disease pathogenesis holds significance for the development of targeted therapies and precision medicine approaches in oncology and immunology.

Sequence Note

Met1-Lys379

Synonyms

Tumor necrosis factor receptor superfamily member 8 (TNFRSF8), CD30L receptor, Ki-1 antigen, Lymphocyte activation antigen CD30, CD30

Instruction

Tainan Headquarter

+886-6-2536677

bd@leadgene.com.tw

Innovation & Research Center

+886-2-27065528

CLD Center

+886-6-2536677

Reconstitution

It is recommended to reconstitute the lyophilized protein in 4 mM HCl to a concentration not less than 200 µg/mL and incubate the stock solution for at least 20 min to ensure sufficient re-dissolved.

Stability & Storage

This product is stable after storage at:


- -20°C for 12 months in lyophilized state from date of receipt.
- -20°C or -80°C for 1 month under sterile conditions after reconstitution.

Avoid repeated freeze/thaw cycles.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at -20°C or lower for long term storage.

Image



SDS-PAGE analysis of recombinant human CD30.

Disclaimer : For Research Use or Further Manufacturing Only.